Dostarlimab with paclitaxel and carboplatin for recurrent or primary advanced endometrial cancer

Dostarlimab in combination with paclitaxel and carboplatin is in clinical development for the treatment of primary advanced or recurrent endometrial cancer. Endometrial cancer is cancer of the lining of the womb. Advanced cancer is when the cancer has spread to other parts of the body; recurrent cancer means the cancer has come back after treatment. Symptoms of endometrial cancer include abnormal bleeding from the vagina, pain during sex, lower back pain and blood in urine. Typically, advanced endometrial cancer is treated by using a combination of surgery, radiotherapy and/or chemotherapy. Prognosis of advanced/recurrent endometrial cancer is poor with limited treatment options. Therefore, there remains a need for additional targeted treatment options to improve outcomes for this patient population.